Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Head of R&D, CMO | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,885 |
Ending reported balance
After 2026-06-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-11 · Exercise / conversion · Acquired 22,515 · Balance 95,165 Row 2 · 2026-06-11 · Sale · Disposed 34,280 · Balance 60,885 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. F2: These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date. Row 3 · 2026-06-12 · Exercise / conversion · Acquired 31,235 · Balance 92,120 Row 4 · 2026-06-12 · Sale · Disposed 31,235 · Balance 60,885 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. F3: These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date. |
| Stock options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.82 · Expires 2035-05-31 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-11 · Exercise / conversion · Acquired 22,515 · Balance 0 F4: The shares sold in this transaction were fully vested. |
| Stock options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.82 · Expires 2035-05-31 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-12 · Exercise / conversion · Acquired 31,235 · Balance 0 F4: The shares sold in this transaction were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested.
F2: These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
F3: These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
F4: The shares sold in this transaction were fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock options (Right to buy) · Derivative | 31,235 | $0.00 Strike: $13.82 | $0.00 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · derivative · entry 6 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,235 shares Expires 2035-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares sold in this transaction were fully vested. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 31,235 | $18.14 | $566,602.90 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · nonDerivative · entry 4 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,885 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. F3 · price: These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 31,235 | $13.82 | $431,667.70 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · nonDerivative · entry 3 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock options (Right to buy) · Derivative | 22,515 | $0.00 Strike: $13.82 | $0.00 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · derivative · entry 5 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,515 shares Expires 2035-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares sold in this transaction were fully vested. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 34,280 | $18.00 | $617,040.00 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · nonDerivative · entry 2 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,885 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. F2 · price: These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 22,515 | $13.82 | $311,157.30 |
DisclosureSEC source: 0001193125-26-269694 · ownership.xml · nonDerivative · entry 1 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 144,700 | $20.43 Strike: $20.43 | $2,956,221.00 |
DisclosureSEC source: 0001193125-26-041334 · ownership.xml · derivative · entry 3 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,700 Underlying: Common Stock · 144,700 shares Expires 2036-02-04 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041334 · ownership.xml · nonDerivative · entry 2 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,165 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041334 · ownership.xml · nonDerivative · entry 1 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,165 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| May 16, 2025 Filed May 19, 2025 16:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 11,765 | $9.00 | $105,826.18 |
DisclosureSEC source: 0000950170-25-074301 · ownership.xml · nonDerivative · entry 1 Botwood Nicholas A.J. · CIK 0002066784 · Head of R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,165 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.